Orexigen Therapeutics promotes two executives
Mr. Cannell joined Orexigen as Executive Vice President, Chief Commercial Officer in 2015 after 27 years at Merck & Co. Inc. where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management.
At Merck, Mr. Cannell's assignments included President of Merck Canada (2012 – 2014) and Head of Marketing and Strategy for MSD Japan (2010-2012).
Earlier he served in general manager roles for a U.S. sales division, as leader of a Merck business unit, managing a multi-billion dollar product portfolio and thousands of employees, and as General Manager, New Commercial Model, U.S..
Mr. Cannell holds a Bachelor of Science degree in Veterinary Science and a Doctor of Veterinary Medicine degree from Washington State University. He has also served in the U.S. Army Reserves (currently inactive) since 1987.
Mr. Keyes is an accomplished executive with 15 years of experience in finance and strategy. He joined Orexigen in 2013 and most recently served as Vice President of Finance.
Prior to joining Orexigen, he was Senior Director of Finance at Amylin Pharmaceuticals which was acquired by Bristol Myers Squibb in 2012.
Previously Mr. Keyes worked in finance and corporate strategy at Amgen, Inc. and at Baxter Healthcare Corporation. He is also a licensed professional engineer and has six years of experience in the environmental engineering industry.
Mr. Keyes holds Bachelor of Science and Master of Science degrees in Civil Engineering from Stanford University and a Master of Business Administration degree from the Anderson School at the University of California, Los Angeles. ■
LATEST MOVES FROM California
- Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
- Endologix appoints John Onopchenko as COO
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
More inside POST